时间回到3月28日，瑞银集团（简称"瑞银"）宣布，中国证监会已对瑞银成为瑞银证券有限责任公司 （简称"瑞银证券"）唯一股东的事项准予备案，瑞银全资控股瑞银证券开启倒计时。 "我们非常看重全资控股的正式完成，瑞银后续有很多安排已经箭在弦上了。"近日，瑞银证券董事长胡 知鸷接受证券时报记者采访时表示。在参加今年的瑞银亚洲投资论坛时，她还多次强调，瑞银证券的股 权变化，是瑞银深耕中国市场36年水到渠成的结果。从一开始，瑞银对中国市场的战略就是全面铺开 的。 难以复制的发展路径 早在2006年，瑞银便耗资17亿元（人民币，下同），拿下了北京证券重组后建立的瑞银证券20%股权。 在这笔交易中，瑞银最为看重的就是北京证券的全牌照优势。 正如前文提到的，瑞银在中国的很多业务布局，都在等待全资控股瑞银证券落地后施展。其中，最为重 要的一点就是强化瑞银的一体化优势。"任何客户来到这里，我们都能为其制定一个专业的综合化服务 方案。当你拥有一整个集团作为背后支撑，在为客户服务时就拥有了满满的自信和底气。"胡知鸷如是 说。 在她眼中，瑞银拥有全牌照业务优势，具备精良稳定的专业团队，前中后台配合起来能迅速拧成一股 绳，抢先抓住商机。这 ...

三生制药、石药集团的巨额BD交易大单，让外界看到了中国创新药产品的价值，也使得"中国研发，海 外授权"的创新药发展逻辑被广泛认可，中国创新药行业的角色正在实现从"跟随者"到"参与者"乃至"贡 献者"的跨越式发展。 巨额BD交易频现 今年以来，中国创新药企业巨额BD交易频现。 证券时报记者李映泉 近一个月以来，中国创新药企对外授权巨额交易捷报频传。先是三生制药公布了一项总金额超60亿美元 的对外授权BD（商务拓展）大单，其12.5亿美元首付款创下此前最高纪录；紧接着是石药集团宣布与 阿斯利康订立战略研发合作协议，总金额达53.3亿美元。 医药魔方数据显示，2024年国产创新药BD交易总金额和首付款分别为523亿美元和41亿美元，双双刷新 历史最高纪录。今年截至5月27日，国产创新药BD总金额已经高达455亿美元，首付款达22亿美元，全 年交易金额有望再创新高。 今年1月，信达生物公告，将一款Delta样配体3（DLL3）新一代抗体偶联药物（ADC）IBI3009的全球 开发、生产和商业化独家权益授权给罗氏，信达生物将获得8000万美元的首付款、最高达10亿美元的开 发和商业化潜在里程碑付款，以及未来基于全球销售 ...

今年汽车行业"反内卷"的第二枪正在打响。 6月23日，全国工商联汽车经销商商会（以下简称"全联汽车经销商商会"）发布的《关于呼吁汽车生产 厂家优化返利政策缩短返利兑现账期的倡议》（以下简称《倡议》）称，在当前市场情况下，汽车生产 厂家对经销商承诺的返利能否及时兑现，对缓解经销商资金压力、改善经销商经营状况至关重要。 此前，部分汽车生产厂家做出缩短供应链账期至60天的承诺，打响了2025年汽车行业"反内卷"的第一 枪。但全联汽车经销商商会表示，要关注到汽车经销商作为汽车产业链的重要一环，同样面临汽车生产 厂家返利兑现账期问题。 所谓返利，是汽车生产厂家激励经销商的重要"指挥棒"：当经销商达成厂家设定的销量目标等考核任务 后，就能获得真金白银的奖励，要么直接拿到现金返现，要么获得下次批售车辆的折扣额度，这种"以 奖代补"的方式能有效降低经销商的进货成本。 但全联汽车经销商商会对比亚迪、宝马、一汽奥迪等42个汽车品牌的经销商返利问题进行的专项调研结 果显示，目前车企对经销商的返利存在多重问题：一是返利构成复杂、存在模糊空间；二是品牌之间兑 现账期差别大；三是返利的兑现形式以及使用方式大多受限。 于是，《倡议》向各汽 ...

Company Overview - Adeia (ADEA) shares increased by 5.2% to $13.74 in the last trading session, supported by higher-than-average trading volume [1] - The stock has shown a 0.5% gain over the past four weeks, indicating a positive trend [1] - Adeia is focusing on innovation in high-growth media and semiconductor markets, which is expected to enhance future technology adoption [1] Earnings Expectations - Adeia is projected to report quarterly earnings of $0.22 per share, reflecting a year-over-year decline of 21.4% [2] - Revenue expectations stand at $88.02 million, which is a slight increase of 0.8% compared to the same quarter last year [2] - The consensus EPS estimate for Adeia has remained unchanged over the last 30 days, suggesting stability in earnings expectations [3] Market Position - Adeia holds a Zacks Rank of 2 (Buy), indicating a favorable outlook in the market [4] - The company is part of the Zacks Technology Services industry, which includes other stocks like QXO, Inc. that have also shown significant gains [4] - QXO, Inc. has experienced a 33.8% return over the past month, highlighting strong performance within the same industry [4] Competitor Analysis - QXO, Inc. has seen a dramatic change in its consensus EPS estimate, increasing by 280% over the past month to $0.09, despite a significant year-over-year decline of 97.2% [5] - QXO, Inc. also holds a Zacks Rank of 2 (Buy), indicating a positive sentiment similar to Adeia [5]

Core Viewpoint - Novo Nordisk has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding an update to the Ozempic label, reflecting positive data from the STRIDE trial for peripheral artery disease [1][3] Group 1: Product Updates - Ozempic (once-weekly semaglutide) is set to have the broadest approved label in the GLP-1 RA class, demonstrating improvements in blood sugar, weight, cardiovascular events, chronic kidney disease, and PAD functional outcomes [5] - The STRIDE trial showed a 13% improvement in maximum walking distance for patients with type 2 diabetes and symptomatic PAD compared to placebo [9] - Novo Nordisk has also filed for a label expansion for Rybelsus, which could make it the first oral GLP-1 RA with proven cardiovascular benefits [4][11] Group 2: Clinical Trial Insights - The STRIDE trial enrolled 792 participants and achieved its primary endpoint, demonstrating significant improvements in walking capacity [8] - The SOUL trial indicated a 14% risk reduction in major adverse cardiovascular events for Rybelsus compared to placebo [11] - The FLOW trial showed a 24% risk reduction in kidney disease progression for semaglutide compared to placebo [14] Group 3: Market Position and Impact - Ozempic is currently marketed in 72 countries, with 7 million people being treated worldwide [16] - Rybelsus is available in 45 countries, with over 2.1 million patients currently treated [17] - The positive outcomes from these trials position Novo Nordisk's products as leading options for managing type 2 diabetes and its associated complications [3][4]

上海黄金交易所黄金T+D 6月23日（周一）晚盘收盘上涨0.41%报781.5元/克； 上海黄金交易所白银T+D 6月23日（周一）晚盘收盘上涨0.76%报8780.0元/千克。 黄金延期 白银延期 ...

本文转自：光明网 日前，我国在高端微特电机领域取得重要突破——杭州贝丰科技股份有限公司（以下简称"贝丰科技"） 正式发布高功率密度无齿槽无刷直流电机。这款电机在功率密度、效率、产品寿命、系统集成、噪音和 振动控制以及可靠性上全面领先，并已形成家族化产品体系。 目前，贝丰科技通过系统化参数矩阵，构建了微特电机领域最完备的家族体系，提供了从微小精密的 10mm到强劲有力的22mm共5种外径规格，并细分为短、中、长三种长度规格，满足从精密医疗器械到 中小装备的各种空间布局和负载需求。 同时，贝丰科技的电机还展现了深厚的技术底蕴与工程化能力，针对世界上最严苛的工况开发了专用电 机，如医疗高温灭菌、化工腐蚀防护、强冲击振动等特殊场景。这种全方位的环境抗性覆盖，将电机的 可靠性推向了新的高度。 依托本土化供应链的深度整合、关键原材料的国产化突破以及智能化产线带来的规模效应，贝丰科技将 高性能无刷无齿槽电机的性价比大幅提升，有望推动人形机器人的快速落地。同时，凭借本土化制造和 敏捷供应链管理，贝丰科技实现了更快的订单响应与交付，保障了国内企业产品研发和生产的连续性。 （战钊） 以其推出的主要应用于灵巧手的10mm外径电机为 ...

WTI 8月原油期货收报68.51美元/桶。 NYMEX 7月汽油期货收报2.2182美元/加仑，NYMEX 7月取暖油期货收报2.3631美元/加仑。 NYMEX 7月天然气期货收报3.6980美元/百万英热单位。 ...

Core Viewpoint - The ARK Innovation ETF (ARKK), led by Cathie Wood, has shown significant recovery and outperformance compared to the S&P 500 Index, driven by a favorable market environment and strategic positioning in high-growth sectors [5][11]. Group 1: Performance Overview - ARKK shares surged from $33 to $160 during the post-COVID bull market, but subsequently fell to under $40 due to market corrections in 2022 [3]. - Over the past year, ARKK has gained 61.26%, significantly outperforming the S&P 500's 9.87% return [5]. Group 2: Market Conditions - The tech-heavy Nasdaq 100 Index ETF has risen from approximately $400 to over $500, indicating a strong bull market that benefits high-growth stocks like those in ARKK's portfolio [8]. - The current market environment is characterized by a robust IPO market, which presents new growth opportunities for ARKK [10]. Group 3: Strategic Positioning - ARKK is focused on industries with strong growth potential, such as artificial intelligence, robotics, and digital assets, which are expected to continue outperforming as these technologies mature [9]. - The team has capitalized on new IPOs, exemplified by their investment in Circle Group, which saw its stock price increase from $64 to $300 shortly after its debut [10].

Core Insights - MariTide, a novel obesity treatment, has shown significant efficacy with up to ~20% average weight loss in individuals without Type 2 diabetes and ~17% in those with Type 2 diabetes, without reaching a weight loss plateau at 52 weeks [1][3][4] - The treatment also resulted in substantial improvements in cardiometabolic health, including reductions in HbA1c levels and various cardiovascular risk factors [3][4][5] - The Phase 3 MARITIME studies are set to evaluate MariTide's safety and efficacy in broader populations, including those with atherosclerotic cardiovascular disease and heart failure, with initiation planned for 2025 [2][6] Company Overview - Amgen is advancing MariTide as a long-acting peptide-antibody conjugate administered monthly or less frequently, aiming to enhance patient adherence and long-term weight management [2][4][20] - The company has a robust pipeline addressing obesity, including both oral and injectable treatments, leveraging its expertise in genetic research to optimize therapeutic outcomes [21][22] Clinical Study Details - The Phase 2 study enrolled 592 adults, divided into two cohorts based on the presence of Type 2 diabetes, with significant weight loss observed across various dosing regimens [8][9] - The Phase 1 pharmacokinetics low dose initiation study demonstrated that lower starting doses improved gastrointestinal tolerability without compromising efficacy [4][5][15] Future Directions - The ongoing Phase 3 studies will further assess MariTide's impact on chronic weight management and its potential benefits for patients with obesity-related conditions [6][10] - Amgen plans to initiate additional Phase 3 studies targeting cardiovascular diseases and obstructive sleep apnea in 2025, expanding the therapeutic applications of MariTide [2][6]